AbbVie announced a $1.4 billion investment to build a 185‑acre manufacturing campus in Durham, North Carolina, near the Research Triangle Park. The new facility will integrate advanced manufacturing and laboratory technologies with artificial intelligence to support the production of the company’s immunology, neuroscience and oncology medicines.
The campus will serve as AbbVie’s U.S. center of excellence for small‑volume parenteral drug product manufacturing and will support the company’s growing pipeline, reinforcing its strategy to diversify beyond Humira and strengthen its competitive position in specialty therapeutics. Construction will begin in 2026, with completion expected by the end of 2028, and the company plans to hire 734 people—including engineers, scientists, manufacturing operators and laboratory technicians—over the next four years.
"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina."
The $1.4 billion outlay is part of AbbVie’s broader $100 billion commitment to U.S. research and development and capital investments over the next decade, underscoring the company’s focus on building domestic manufacturing capacity for its next‑generation immunology drugs such as Skyrizi and Rinvoq, as well as oncology and neuroscience products. The investment positions AbbVie to meet growing demand for specialty therapeutics while reducing reliance on legacy products and enhancing its ability to scale new therapies efficiently.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.